Crestor Rhabodomyolysis Cases At 10 Mg Dose Prompt Renewed Call For Drug’s Removal
This article was originally published in The Pink Sheet Daily
Executive Summary
Public Citizen cites 11 additional cases of rhabdomyolysis in pressing for Crestor’s removal. AstraZeneca revises drug administration guidelines in “Dear Doctor” letter to U.K. physicians.
You may also be interested in...
Crestor Safety Data Under FDA Review; 11 Reports Of Rhabdomyolysis At 10 Mg Dose
The agency appears unlikely to make a significant change in the regulatory status of the statin in the near term; FDA notes that most of the reported cases of rhabdomyolysis and renal failure could be attributed to the underlying disease or concomitant medications. Public Citizen renews call for Crestor's withdrawal in Lancet article.
Crestor Safety Data Under FDA Review; 11 Reports Of Rhabdomyolysis At 10 Mg Dose
The agency appears unlikely to make a significant change in the regulatory status of the statin in the near term; FDA notes that most of the reported cases of rhabdomyolysis and renal failure could be attributed to the underlying disease or concomitant medications. Public Citizen renews call for Crestor's withdrawal in Lancet article.
Crestor European Label Changes Prompt FDA Public Health Advisory; Safety Review Ongoing
FDA is using European label update as an opportunity to remind physicians of three "key safety messages" contained in Crestor's U.S. label. FDA is not recommending changes to the U.S. label, pending an evaluation of postmarketing reports of rhabdomyolysis.